These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33629878)

  • 1. Role of Short-Term Neoadjuvant Chemoradiotherapy for Potentially Resectable Pancreatic Cancer.
    Okano K; Suto H; Oshima M; Ando Y; Matsukawa H; Kamada H; Kobara H; Masaki T; Suzuki Y
    Am Surg; 2022 Jun; 88(6):1298-1303. PubMed ID: 33629878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
    Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
    Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Okano K; Suto H; Oshima M; Maeda E; Yamamoto N; Kakinoki K; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
    Ann Surg Oncol; 2017 Sep; 24(9):2777-2784. PubMed ID: 28608121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
    Endo Y; Kitago M; Aiura K; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Nakano Y; Itano O; Fukada J; Masugi Y; Kitagawa Y
    World J Surg Oncol; 2019 Aug; 17(1):145. PubMed ID: 31420046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant chemoradiotherapy for resectable pancreatic cancer: A retrospective study.
    Suto H; Matsukawa H; Fuke T; Nagao M; Ando Y; Oshima M; Yamana H; Kamada H; Kobara H; Okuyama H; Kumamoto K; Okano K
    Pancreatology; 2024 May; 24(3):431-436. PubMed ID: 38383175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis.
    Yoon MS; Lee HS; Kang CM; Lee WJ; Keum J; Sung MJ; Kim SS; Park MS; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Hwang HK; Bang S
    Gut Liver; 2022 Jan; 16(1):118-128. PubMed ID: 34140428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
    Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
    Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
    Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
    J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borderline resectable pancreatic ductal adenocarcinoma.
    Suto H; Oshima M; Ando Y; Matsukawa H; Takahashi S; Shibata T; Kamada H; Kobara H; Masaki T; Kumamoto K; Suzuki Y; Okano K
    HPB (Oxford); 2023 Jan; 25(1):136-145. PubMed ID: 36307256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
    Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy.
    Takaichi S; Tomimaru Y; Kobayashi S; Toya K; Sasaki K; Iwagami Y; Yamada D; Noda T; Takahashi H; Asaoka T; Tanemura M; Doki Y; Eguchi H
    Ann Surg Oncol; 2023 Apr; 30(4):2458-2468. PubMed ID: 36575288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
    Barnes CA; Aldakkak M; Christians KK; Clarke CN; Dua K; George B; Ritch PS; Kamgar M; Hall WA; Kulkarni N; Erickson BA; Evans DB; Tsai S
    Surgery; 2020 Sep; 168(3):440-447. PubMed ID: 32641278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer.
    Suto H; Okano K; Oshima M; Ando Y; Matsukawa H; Takahashi S; Shibata T; Kamada H; Kobara H; Tsuji A; Masaki T; Suzuki Y
    Pancreas; 2022 Mar; 51(3):269-277. PubMed ID: 35584385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma.
    Eid M; Ostřížková L; Kunovský L; Brančíková D; Kala Z; Hlavsa J; Janeček P; Kosíková I; Blažková M; Slabý O; Mayer J
    Neoplasma; 2021 Jan; 68(1):1-9. PubMed ID: 32880468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
    Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
    Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.